Avita Medical, Inc. · NASDAQ:RCEL

Avita Medical — Shareholder Meeting (November 2010)

35 slides from Avita Medical's shareholder meeting presentation, Nov 30, 2010

  1. Slide 1: Annual General Meeting, Perth, 30 November 2010

    William Dolphin, Ph.D. Chief Executive Officer Galatéa de las esferas Salvador Dalí, 1952 Annual General Meeting Perth, Australia 30 November 2010

  2. Slide 2: Forward-looking statements

    2 This presentation may include forward‐looking statements. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “potential”, “intend”, “plan”, “believe”, “target”, “may”, “assume” or similar expressions. These forward looking state

  3. Slide 3: Agenda

    3 ƒ Review of original Strategic Plan ƒ Performance to date ƒ Initial product: ReCell Spray‐On Skin − Product Description − Market Opportunity

  4. Slide 4: Our Mission

    4 ƒ Our Mission: Create a leading global healthcare company in the field of regenerative medicine and tissue engineering, providing innovative, highly differentiated and cost‐effective solutions that address the needs of patients, clinicians and healthcare systems while delivering above average retu

  5. Slide 5: Goal: Regrow, replace, restore function of tissues

    5 ƒ Goal: Regrow, replace, restore function of tissues, organs or limbs damaged, lost or non‐functional (e.g., trauma, disease, senescence). ƒ Fundamental change to practice of medicine ƒ All tissues and organs – in theory – have capability to regenerate ƒ Initial Product : ReCell® Spray‐On Skin

  6. Slide 6: Three-year strategic plan by year

    6 Year 1 (30 June 2009) Year 2 (30 June 2010) Year 3 (30 June 2011) ™ Assess: ™ Build organisation: ™ Implement Sales & ¾ Organisational structure ¾ Put teams in place: Marketing Plan ¾ Personnel management, ops, sales ¾ Mixed model: direct & ¾ Market – ReCell Go/No Go ¾ Revamp Operations & distribu

  7. Slide 7: Strategic priorities

    7 ƒ Increase sales revenues in high value markets ƒ Implement “continuous improvement” models to operations ƒ Tighten management of working capital ƒ Obtain regulatory approvals in key markets ƒ Strengthen product portfolio and expand intellectual property

  8. Slide 8: Revenue, $M

    8 •Increase sales revenues in high value markets • Focused efforts on key markets, establishing KOLs and centres of excellence Revenue, $M • 2‐year growth of 99%: • 2008: $1.9M • 2009: $3.2M • 2010: $3.9M

  9. Slide 9: Gross Margin

    9 • Implement “continuous improvement” models to operations • Gross margins improved with continued gains in manufacturing efficiencies. • 2‐year improvement of 97% Gross Margin • 2008: 38% • 2009: 54% • 2010: 75%

  10. Slide 10: Operating Loss, $M

    10 •Tighten management of working capital • Ongoing efforts at cost containment and improved efficiencies continue to positively impact cash flow. Operating Loss, $M • 2‐year reduction of operating losses of of 78%: • 2008: $12.5M • 2009: $5.1M • 2010: $2.7M* • Corporate restructure: Stock repurchas

  11. Slide 11: Obtain regulatory approvals in key markets

    11 ƒ Obtain regulatory approvals in key markets − Regulatory clearance in Europe (CE Marked), Australia (TGA), China (SFDA) − US FDA trials underway ▪ US$2M grant from US DoD (AFIRM) – Burns ▪ US$2M contract from US DoD (OTT) – Scar

  12. Slide 12: US DoD (AFIRM) burns trial

    12 ƒ $1.95 M funding from US DoD (AFIRM) ƒ Primary Objective: Demonstration of safety and efficacy of ReCell in the treatment of acute burns in comparison to current standard‐of‐care, split‐thickness skin graft (STSG) − US FDA product approval ƒ Endpoints: − Time to healing − Morbidity (infections,

  13. Slide 13: US DoD (OTT) scar trial

    13 ƒ $1.9 M contract with US DoD (OTT) ƒ Primary Objective: Demonstration of safety and efficacy of ReCell in the treatment of scars resulting from meshed, split‐thickness skin graft (STSG) − US FDA product approval ƒ Endpoints (proposed): − Elimination of Scarring (matching to surrounding, undamage

  14. Slide 14: Strengthen product portfolio and expand intellectual property

    14 ƒ Strengthen product portfolio and expand intellectual property − 7 patents granted (US, PCT, Australia, Japan) − 6 applications pending

  15. Slide 15: Market Opportunities

    Market Opportunities 2013 Market Opportunities 6 Wound Management & Regenerative Medicine 5 Infusion / Delivery Degree of Innovation 4 Ortho / Spinal Implants Orthobiologics 3 Steroid-Eluting Electrode 2 Antibiotic Bone Cement 1 Drug-Eluting Stents *Bubbles denote market size 0 0.0% 5.0% 10.0% 15.0%

  16. Slide 16: Geographic expansion

    16 ƒ Australia/New Zealand ƒ Europe − Expand beyond current UK, France, Germany ƒ Asia − Taiwan − China (forming JV) − India/SE Asia ƒ Middle East ƒ Russia ƒ United States

  17. Slide 17: Avita's regenerative technology

    17 Avita’s regenerative technology: ƒ Harnesses body’s intrinsic ability to heal itself and packages it into an easy‐to‐use bedside kit for the clinician. ƒ Patients: Provides improved outcomes. ƒ Surgeon/Clinician: Easy, fast and effective with reduced morbidity. ƒ Healthcare Provider: Reduced cost

  18. Slide 18: Applications

    18 Applications: ƒ Burns, scalds and donor sites associated with grafts ƒ Scar revisions to improve colour, texture & function ƒ Pigmentation disorders such as Vitiligo ƒ Epidermal defects such as naevi, acne, discolouration ƒ Prophylactic aesthetic rejuvenation procedures

  19. Slide 19: Patient results over time

    19 Day 1 Prep and debridement 3 Weeks post ReCell 10 Months post ReCell

  20. Slide 20: Neck pre-treatment and 12 months post ReCell

    20 Neck pre‐treatment 12‐months post ReCell®

  21. Slide 21: Pre-ReCell and 10 months post-ReCell

    21 Pre‐ ReCell 10 month post‐ ReCell

  22. Slide 22: Pre-ReCell and 12 months post-ReCell

    22 Pre‐ ReCell 12 month post‐ ReCell

  23. Slide 23: Pre-ReCell and 12 months post-ReCell

    23 Pre‐ ReCell 12 month post‐ ReCell

  24. Slide 24: Skin Structure and progenitor cells

    Skin Structure Openings of Sweat Glands Horny Layer | Granular Layer EPIDERMIS EST ease ee etter r o<— Prickle-Cell Layer . a Progenitor SKIN _\+———_ Basal Layer cells DERMIS - Subaceous Gland one ene eee eee = 4 ‘ — - Blood Vessels Hair Follicle ———= : Le y Nerves Subcutaneous Fatty Tissue avita

  25. Slide 25: ReCell procedure steps

    25 1. Thin, split‐thickness biopsy (200 x 200 x 0.2 mm) of similar skin (‘site matched’) 2. Biopsy incubated in enzyme ‘cocktail’ approx 20 min 1. 2. 3. Biopsy removed from incubator, mechanically agitated to separate cells 4. Cells rinsed in ‘buffer cocktail’ 3. 4. 5. Suspension filtered 6. Suspens

  26. Slide 26: Cells collected from dermal-epidermal junction

    26 ƒ Cells collected from dermal‐epidermal junction include: − Keratinocytes − Melanocytes − Fibroblasts − Langerhans Cells − Un‐differentiated Basal cells ƒ These cells: − Are not yet terminally differentiated − Pre‐confluent − Are highly proliferative − Cultured in‐situ − Migrate evenly across the

  27. Slide 27: ReCell suspension sprayed onto wound surface

    27 Result: ‘normal’, healthy, new skin with full complement of constituent ReCell suspension cells types, including melanocytes, sprayed onto keratinocytes, fibroblasts and basal wound surface cells in proper proportion Disaggregated Cell signalling cells migrate encourages and directs over wound ar

  28. Slide 28: Wound Care, Plastics, Aesthetics applications

    28 Wound Care Plastics Aesthetics ‐ Burns ‐ Scar remodelling ‐ Cosmetic relief ‐ ReCell Alone ‐ Pre‐existing ‐ Acne scars ‐ Combination with ‐ Burn, graft scars ‐ Hyper or hypo‐ other treatments ‐ Surgical scars pigmentation (e.g., mesh grafts, ‐ Biopsy ‐ Liver spots dermal substitutes) ‐ Mohs surge

  29. Slide 29: ReCell Markets

    ReCell® Markets Burns 450,000 Burns requiring surgical intervention (2) Plastic / 580,000 (US) Treatments sought from plastic Dermatology / surgeons for scar remodeling. (3) Reconstructive Vitiligo 200,000 ? Reported cases seeking treatment (prevalence: 2% of population ~ 12 million) (4) Aesthetics

  30. Slide 30: Competition

    Competition Skin graft Cultured epithelia (auto or allo) Artificial skin Dermal matrixes ReCell Spray-On Skin * Standard of care + Specific graft procedure inexpensive + Rapid procedure + Large coverage * Small donor site + Low infection + Large coverage * No donor site + Low infection / reject + Re

  31. Slide 31: Competition

    Competition Skin graft: Cultured epithelia (autologous, allogeneic or xenogeneic) Dermal matrixes Spray-on (ReCell) 3M Health Care Baxter Carrington Laboratories, Inc. ConvaTec, Ltd. Covidien, Ltd Derma Sciences GlaxoSmithKline Plc Healthpoint, Ltd. Advanced BioHealing Ethicon Fidia Farmaceutici s.p

  32. Slide 32: Management team

    32 William F. Dolphin, Ph.D., CEO; 28 years international executive experience; significant M&A experience. Andrew Quick, VP Research & Technology; 20 years medical device experience; expertise in design, development and clinical research. Lorraine Glover, General Manager, Asia Pacific; 20 years in

  33. Slide 33: Major progress on all fronts

    33 Major progress on all operational, strategic and corporate fronts: ƒ Increased sales revenues ƒ Improved margins ƒ Decreased cash burn ƒ Support of key influential surgeons and Centres of Excellence ƒ Support of US Dept of Defense ƒ Experienced management team in place ƒ Unique, ‘paradigm‐shiftin

  34. Slide 34: 34

    34

  35. Slide 35: Thank you

    Thank you avita

Avita Medical — Shareholder Meeting (November 2010) on 6ix